All Radiopharmaceuticals and Radiochemicals listed below are prepared in-house using the MIR Cyclotron Facility & Nuclear Pharmacy . This list is not comprehensive, but does highlight the compounds available.

Compound w/ IsotopeTypical Utilization
[F-18] FDG* (Fluorodeoxyglucose)Imaging agent of glucose uptake, making it useful for imaging tumors. It is the standard imaging agent used in PET for cancer patient management
[F-18] FLT* (Fluorodeoxythymidine)Indicated use to image cellular proliferation, FLT is a nucleoside analog that accumulates in proliferating cells. May validate the efficacy of chemotherapy in patients with lymphoma and other cancers.
[F-18] FFNP* (Fluorofurylmethylidene dioxynorpregnenedione)Indicated use as an imaging agent that binds to progesterone receptors (PgR) in progesterone-responsive tissues. In PgR-positive breast cancer, it may be used to quantitate hormone receptor status.
[F-18] ISO-1* (Sigma-1)Indicated use as a promising imaging agent for evaluation of the proliferative status of solid tumors.
[F-18] NOS* (Nitric oxide synthase)Used to evaluate the feasibility of imaging cellular iNOS activity.
[F-18] VAT* Indicated use to quantify the vesicular acetylcholine transporters in the brain synapses in the central nervous system CNS.
[F-18] FES* (Fluoroestradiol)Indicated use as an imaging agent of estrogen receptor content in breast tumors.
[F-18] FTT* (FluorThanatrace)An imaging agent of PAR activity that may aid in the selection of patient that will benefit from PARP inhibition treatments.
[F-18] AV-1451* & [F-18] MK6240*Inquire about availability.
[F-18] NaFImaging of bone abnormalities.
[F-18] FDOPA* (Fluorodopa)(Nucleophilic)Indicated use as imaging agent of movement disorders, and brain malignancies.  It may also be useful for imaging other malignant diseases such as neuroendocrine tumors, pheochromocytoma and pancreatic adenocarcinoma.
[C-11]PIB* (Pittsburgh Compound B)Indicated uses as an amyloid imaging agent
[C-11] CHO* (Choline)Imaging agent used to detect sites of prostate cancer that have returned despite treatment (recurrent prostate cancer). It may be used when other imaging has not been helpful.
[C-11] Palmitate*Palmitate is the most accurate method to measure myocardial fatty acid metabolism, permitting measurement of fatty acid uptake, oxidation and storage.
[C-11] PKAB*An antagonist imaging agent for Kappa opioid  receptor.
[C-11] Raclopride*Indicated use as reversible imaging agent of D2/3 receptors.
[C-11] Acetate*Myocardiol metabolism and indicated use as a tumor imaging agent in prostate cancer.
[C-11] MHEDSympathetic nervous system imaging. Targets the norepinephrine transporter.
[C-11] S1P1*[11C] TZ3321 used assess the inflammation response that will not have genetic phenotype limitation.
[C-11] NMB*Indicated use as an imaging agent for D2 receptors.
[N-13] Ammonia*Indicated use for diagnostic Posit imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
[O-15] Water*Indicated use as an imaging agent of blood flow. Because it is washed out in proportion to the regional blood flow and its kinetics are not affected by metabolism it can be used to assess blood flow.
[O-15] Gases (O2, CO)*Inhalation of  [15O]O2 and [15O]CO measure oxygen consumption and blood volume.
[Cu-64] LLP2A*Imaging of myeloma.
[Cu-64] ATSMImaging of hypoxia.
[Zr-89] Herceptin*HER2 positive breast cancer imaging agent.

 * compound is available for human use

All Radiochemicals listed below are available on-demand and can be shipped to facilities with active radiation approvals.

  • [Cu-64] Copper Chloride (API Grade under DMF)
  • [Cu-64] Copper Chloride (Radiochemical Grade)
  • [Zr-89] Zirconium Oxalate
  • [Br-76] Bromide
  • [Ga-68] Gallium Chloride

Quantitative Imaging Informatics Resource (QI2R)

The QI2R was established to:

  • ensure standardized evaluation of radiotracer performance
  • facilitate the movement and management of data throughout the PET-RTRC

The QI2R has two primary functions:

  • quantitative image analysis of Center image datasets
  • development and management of informatics pipelines

The QI2R will provide guidance and expertise in quantitative imaging to be employed by TR&Ds.  In doing so, the QI2R will promote standardized/unified image analytics across Center activities and promote training of Center members.

The QI2R will develop and implement advanced quantitative imaging pipelines to characterize radiotracer performance. 

To facilitate the movement and management of data throughout the Center, the QI2R developed the co-clinical database (CCDB).  The CCDB is built on XNAT, a widely used open source imaging informatics platform.  XNAT is a web-based software platform designed to facilitate common management and productivity tasks for imaging and associated data.  A fine-grained access control system ensures that users are restricted to accessing only authorized data.  XNAT also includes a web services API for programmatic access and a plugin architecture for extending XNAT’s core capabilities. For QI2R, data contributors will upload Center-related data and metadata to the CCDB using a secure web application. Data will be organized in study-specific projects that provide access to authorized personnel. 

For more information please email Michelle Hoelscher


Training is available for PET radiochemists and radiopharmacists to synthesize radiotracers produced by the PET-RTRC and scientists who use this technology. We provide opportunities for interested researchers, such as basic scientists with training in preclinical imaging using PET radiotracers and clinician scientists in the design and conduct of human research studies using PET as an imaging modality.

  • Individualized hands-on training is available
  • 2-3 month lead time is needed

Standardized Procedures (SOPs)

For optimal evaluation of radiotracer performance, Standardized Procedures are available upon request.

For more information please email Michelle Hoelscher.